Therapeutic monoclonal antibodies (mAbs) are potent new tools for a molecular targeted approach to modify the course of multiple sclerosis (MS). Besides natalizumab, which was approved in 2006, three ...

MS is an autoimmune disorder in which the immune system attacks myelin, the protective covering of nerve fibres in the brain ...

Experts in multiple sclerosis discuss the potential introduction of a subcutaneous form of ocrelizumab to the market in late 2024 and how they plan to incorporate it into their treatment algorithms.

A trial found six weeks of yoga improved sleep quality and reduced fatigue in people with MS, suggesting its use as a ...

After MS causes symptoms in her hands, columnist Desiree Lama lands on making beaded curtains as a way to improve her fine motor skills.

Researchers from Bonn and Erlangen identify the protein MLC1 as a target antigen in multiple sclerosis (MS); a chronic inflammatory disease of the central nervous system caused by the immune system. B ...

Immediately after occupational therapy (OT), people with multiple sclerosis may show small improvements in daily functioning and mental health-related quality of life (HR-QoL), but OT may have little ...

CombiRx is a randomized clinical trial to determine if the combined use of interferon beta-1a (IFN) and glatiramer acetate (GA) is a measurably better therapy than either agent used individually in ...

Many symptoms of MS are the same as those of other conditions. If you are concerned that you may have MS, make an appointment with your primary care provider. They will discuss your concerns and do a ...

In a study of commonly used treatments for people with multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in meaningful improvements in fatigue, a ...

From baseline to week 12 the adjusted mean difference in Modified Fatigue Impact Scale change was 1.88 and 1.20 for CBT and modafinil, respectively, relative to the combination group. HealthDay News — ...

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI ® (ublituximab-xiiy), to be presented (ACTRIMS) annual forum, being held February 5 – ...